NUCB2/Nesfatin-1: A Potent Meal Regulatory Hormone and its Role in Diabetes by Khalili, Soodabeh et al.
The Egyptian Journal of Medical Human Genetics 18 (2017) 105–109Contents lists available at ScienceDirect
The Egyptian Journal of Medical Human Genetics
journal homepage: www.sciencedirect .comReviewNUCB2/Nesfatin-1: A Potent Meal Regulatory Hormone and its Role in
Diabeteshttp://dx.doi.org/10.1016/j.ejmhg.2016.10.003
1110-8630/ 2016 Ain Shams University. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of Ain Shams University.
⇑ Corresponding author at: Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
E-mail address: mderakhshan2002@gmail.com (S. Mansoori Derakhshan).Soodabeh Khalili a,b, Mahmoud Shekari Khaniani b, Fatemeh Afkhami b, Sima Mansoori Derakhshan a,b,⇑
aNeurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
bDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Irana r t i c l e i n f o
Article history:
Received 22 June 2016
Accepted 26 October 2016




Type 2 diabetesa b s t r a c t
Background: Nesfatin-1, a newly discovered calcium and DNA binding peptide, originate from nucle-
obindin 2 (NUCB2) precursors and expressed by central and peripheral nervous system, and peripheral
tissues such as digestive organs and adipose tissues. It has the astonishingly large number of chemical
messengers for full appetite and introduced as a potential anorectic factor with ability to modulate body
weight and probably, energy homeostasis.
Nesfatin-1/NUCB2 level in the circulation is elevated after meal intake and decreased during a fast. Its
food intake suppression effect is independent from the leptin pathway, and act via the melanocortin sig-
naling. On the other hand, Nesfatin-1 colocalizes with insulin in pancreatic beta islet cells and has been
shown to increase insulin secretion.
Methodology: PubMed databases were searched for ‘‘NUCB2 or nesfatin-1 or nucleobindin” with the com-
bination of ‘‘diabetes mellitus”. Included papers were further searched manually for additional studies.
The databases were searched up to 2015. Fifty one articles were selected for full text review.
Result: Centrally controlled Nesfatin-1 was stated to raise peripheral and hepatic insulin sensitivity by
reducing gluconeogenesis and stimulating peripheral glucose uptake in vivo.
Conclusion: Nesfatin-1 has gain attention as a new target to generate, drug for treatment of endocrine
nutritional and metabolic disorders like obesity and type 2 diabetes mellitus.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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The endocrine system generates and discharges hormones that
regulate the essential body functions. The hypothalamus, vital
integrator of glands in the brain, plays main roles in controlling
food intake and is a rich source of satiety regulatory peptides
which participate in the long-term energy balance [1]. One of such
peptides which are recognized recently is Nesfatin-1. Beside secre-
tion of Nucb2 from hypothalamus, this peptide also is released
from endocrine cells in the pancreatic beta-cells, intestinal and
gastric mucosa and found in peripheral places such as the muscle
and adipose tissues.
NUCB2 was first recognized in numerous regions of the
hypothalamus and pancreatic beta-cells, showing the possible con-
tribution of NUCB2 in the regulation of insulin secretion, hunger
and fat storage [2]. Nesfatin-1 has rapidly proven as a novel man-
ager of appetite, energy and glucose homeostasis and insulin secre-
tion, with significant values to the etiology of metabolic diseases
including diabetes and obesity [3–5]. Nesfatin-1 is also involved
in the regulation of some other physiological procedures including
anxiety and drinking [6–10].2. Nucleobindins
In the early 1990s, a protein was recognized in mouse [11] and
human cell lines [12] and named nucleobindin or DNA binding/EF-
hand/acidic amino acid rich region (NEFA). This peptide includes
various efficient domains as well as an N-terminal side, a leu-
cine/isoleucine rich domain, a DNA binding domain and an
assumed nuclear targeting peptide, while the C-terminal region
has two Ca2+-EF-hand motifs and a leucine zipper motif [13].
So far, two nucleobindins have been recognized, that is nucle-
obindin 1 (NUCB1 or CALNUC, rat: NM 053463.1) [14] and nucle-
obindin 2 (NUCB2 or NEFA, rat: NM 021663.2) [15].
Nucleobindin-1 and Nucleobindin-2 have Ca2+ binding multi-
domain that take 62% amino acid identity while two distinct and
unlinked genes encode them [16]. NUCB2 and NUCB1 are identified
to secrete proteins (Miuraet al. 1992), however their roles
remained mainly unidentified [17]. They are homologous gene
family and probably derived from one EF-hand progenitor with
four domains [18]. NUCB2 is 40 residues smaller than NUCB1and
is about a 50-kDa protein [19].2.1. Nucleobindin 1 and its functions
In 1992, Nucleobindin1 was first found in a culture supernatant
of a B lymphocyte cell line from mice disposed to an autoimmune
disorder, systemic lupus erythematosus. Such discovery displayed
its role in autoimmunity and apoptosis [15]. Nucleobindin-1 is
encoded by NUCB1 gene containing 13 exons which is located on
the 19q13.33 (accession no: NM_006184.5).
Researchers found that NUCB1 is widely expressed in many tis-
sues. The cellular localization of Nucleobindin-1 has been inconsis-
tently recommended to be a secreted nuclear protein [20,15], a
resident endoplasmic reticulum protein.
NUCB1 has ability to bind Ca2+ and DNA [19]. Its Ca2+-binding
region is available at the central part of the protein having two
EF hand motifs with the acidic domain (residues 253–316) [20].
Leucine amino acid in NUCB1 is known to be contributed in dimer-
ization as well. The leucine zipper domain is ended by a C-terminal
region that is assumed to be essentially unstructured. The compo-
sition of NUCB1 proposes various intracellular roles for this protein
[19].
NUCB1 has been shown to take part significantly in Ca2+
Homeostasis [21]. It is related with other proteins, including Gproteins [21] and cyclooxygenases [22]. NUCB1 is attached to Ca2+
as determined by Ca2+ edges, which proposes that NUCB1 might
show an essential role as an agonist-releasable Ca2+ store in the
luminal Golgi [21]. NUCB1in neutrophils are localized in the ER
and Golgi system, together with cyclooxygenase-2 (COX-2) and
act in the production of prostanoid. NUCB1 interacts with COX-2
with high affinity resulting in an enhance of PGE2 generation [9].2.2. Nucleobindin2
The nucleobindin-2 (NUCB2) [23], with extremely protected
sequence across mammalian and non-mammalian vertebrates,
includes 420 amino acids [16], including a polypeptide formed of
396 amino acids, followed by a 24 amino acid signal peptide is
placed both on the plasma membrane and in the neuroplasm [24].
This gene is located on the 11q151, and its amino acid sequence
is greatly conserved in rats (95% homology) and mice (87.4%
homology)[25], and consists of 14 exons covering 54785 nucleo-
tides (accession No. NC_000011.9), the mRNA of 1612 nucleotides,
which just nucleotides 246–1508 are translated (accession No.
NM_005013.2) [26].
NUCB2 has also been identified by additional names which
include AI607786, CALNUC, DNA-binding protein NEFA and NEFA
[27]. It was newly recognized as one of 600 genes that is stimu-
lated by the diabetic medicine, troglitazone, in SQ-5 cells, a human
lung cancer-cell line [13].
Differential posttranslational proteolytic handling of NUCB2 by
prohormone convertase makes three active cleavage peptides,
namely 1–82 AA (Amino Acid) Nesfatin-1, 85–163 AANesfatin-2,
and 166–396 AA Nesfatin-3 [24]. The structure of the 82-amino
acid molecule nesfatin-1 is the effect of posttranslational cleavage
by the precise convertases PC3/1 and PC2 Nesfatin-1 has an exten-
sive homology among humans and mammals, above 85%, also in
the lower vertebrates [28]. Nesfatin-1 amino acids are coded by
nucleotides between Exon-3 and 5 of the NUCB2 gene.
Until now, several biological actions have been recognized for
nesfatin-1 [29], while none have been explained for nesfatin-2
and nesfatin-3 [13]. On the other hand, it is important to mention
that nesfatin-2 and nesfatin-3 have obtained fewer attention until
now and more work are needed to found or regulate out if these
cleavage yields have biological action [30].
The nesfatin-1 molecule is composed of several domains: signal
peptide in N-terminal, Leu/Ile rich domain, DNA-binding domain,
signal for nuclear directing, two motifs for Ca2+-EF-hand and leu-
cine zipper domain [28].
The construction of nesfatin-1 is as well tripartite, the section
beginning from the N-terminal end up to 23 amino acids is named
N23, the central fragment from 23 to 53 is called M30, and the part
from the 53rd to 82 near the carboxyl terminus is named C29 [31].
The M30 active core has been shown to play the key function in
the stimulation of physiological consequences of this peptide,
especially in anorectic reactions [32].
There are numerous arginines and lysines inside the nesfatin-1,
telling additional treating of this protein processing enzymes [28].
Still the physiological act of Nucleobindin-2 is incompletely
defined. It has been stated that Nesfatin-1 but not Nucleobindin-2
has anorexigenic effect as Nesfatin-1 limited food intake while a
Nucleobindin-2 mutant that could not be treated into Nesfatin-1
hasnot this effect. Lately Broberger et al. stated that Nucleobindin-
2 co-localizes with insulin in rat and human pancreatic b cells [24].3. NUCB2/nesfatin-1 distribution
NUCB2/nesfatin-1 was first identified in several regions of the
hypothalamus, later, it was found not only in the hypothalamus
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pituitary, and cardiac autonomic nuclei in spinal cord, in human
and rat pancreatic beta-cells [33]. Foo et al. 2010 has been demon-
strated the detection of nesfatin-1 and insulin co-localization only
in pancreatic beta-cells but not in other islet cells or in the exocrine
pancreas. Expression of NUCB2/nesfatin-1 in pancreatic beta-cells
indicates its possible involvement in the regulation of insulin
secretion [34]. Expression of nesfatin-1 mRNA has been established
to be 10-fold more in gastric mucosa compared in the brain, show-
ing the stomach is the key basis of circulating nesfatin-1 [35].
Nesfatin-1 has been described to pass the brain-blood-barrier
through a non-saturable membrane, resulting the possibility that
nesfatin-1 secreted from the stomach can act centrally [36,37].
Expression of NUCB2 and nesfatin-1 has also been released in adi-
pocytes. It is notable that this expression is chiefly obvious in the
subcutaneous fat tissue cells [32].
The comprehensive supply of NUCB2/nesfatin-1 in the hypotha-
lamus and brain stem areas is supposed to be revealing of an
essential role for nesfatin-1 in the regulation of energy
homeostasis.
Nucleobindin-2 (NEFA) was stated to be localized in the cyto-
plasm, on the plasma membrane, as well as being secreted in by
both peripheral tissues and CNS [16].4. Nesfatin-1 functions
4.1. The anorexic effects of nesfatin-1
This factor was termed nesfatin-1 (for NEFA/NUCB2-encoded
satiety- and fat-influencing proteins) [34]. It has been shown that
nesfatin-1 is regulated by hunger and satiety and it has demon-
strated an anorexigenic activity [38]. Also, NUCB2-1 has been
demonstrated to cross the blood-brain barrier bi-directionally in
a non saturable way [39], the half-life of NUCB2 messenger ribonu-
cleic acid (mRNA) was just about 6 h [31].
In the study of Oh-I et al. [2], it has been proposed that intrac-
erebroventricular (ICV) injection of the central 30 amino acid seg-
ment of nesfatin-1 decreases food intake in a dose-dependent
mode in rats. The amino acid sequence of this mid-segment is like
to that of a-melanocyte-stimulating hormone (a-MSH) and
Agouti-related peptides (AgRP) In contrast, ICV injection of
nesfatin-2 and nesfatin-3 was without consequences [17]. In the
line with this finding, ICV injection of antibodies against
nesfatin-1 augmented appetite, indicating that endogenous
nesfatin-1 contributes in appetite regulation [40]. This finding sug-
gests that agonists of nesfatin-1 may be useful for obesity thera-
peutics in the future.
Because ICV injection of nesfatin-1 can inhibit food intake in
leptin-receptor-mutant rats, it has been postulated that its food
intake inhibition is independent of the leptin pathway. It suppress
food intake via the melanocortin signaling [41].
To date numerous studies have completed these primary results
and have recognized that injections of nesfatin-1 centrally or
peripherally make an important decrease of food intake in rodents
[19,41,42] supporting the act of endogenous nesfatin-1 in the mon-
itoring of feeding. It has been revealed that fasting decreased the
expression of NUCB2 mRNA in gastric system, suppresses gastric
emptying, suggesting that nesfatin-1 may influence digestion and
absorption. Gastric emptying suppression has also been reported
following ICV injection of nesfatin-1. However in the recent study
in 2016, food intake did not change in transgenic mice overexpres-
sion of nesfatine1, in normal diet and upon over feeding with high
fat diet, and these mice showed increase in body weight. These
results indicate that nesfatin may be involved in triglyceride accu-
mulation and insulin resistant independent of energy intake [43].4.2. Effects on glucose control and insulin release
4.2.1. Expression in the pancreas
Owing to the condensed expression of nesfatin-1/NUCB2 in the
pancreas and the special colocalization of nesfatin-1 immunoreac-
tivity with insulin in endocrine b-cells of rats [32,44] and human
[45], a potential role of nesfatin-1 in glucose control has been sus-
pected. Later on, in 2010, Diggs-Andrew et al. revealed that, hyper-
glycemia activates nesfatin-1 expressions in the hypothalamic
neurons. Additionally, they showed that high level of glucose in
blood improved the release of nesfatin-1 in the endocrine cells of
pancreas [46]. In support of the role for nesfatin-1 in the regulation
of glucose level, Su et al. [43] described that intravenous injection
of nesfatin-1 decreased blood glucose in hyperglycemic db/db
mice. They also reported that this anti-hyperglycemic effect is
not observed in animals with normal level of blood glucose, indi-
cating an insulinotropic action by Nesfatin1 [31,47]. Later, a few
studies confirmed and extended these finding; for example, Yang
et al. in 2012 [48] reported that ICV injection of nesfatin-1 in rats
with diet-induced obesity, resulted in inhibition of hepatic glucose
construction through regulation of hepatic gluconeogenesis [47].
Altogether, these facts show that chronic changes in glucose
concentrations influence the pancreatic NUCB2 expression propos-
ing a controlling action in glucose homeostasis, particularly under
situations of pathologically changed blood glucose levels. Facts up
to now points towards an intracellular or auto/paracrine rather
than endocrine mode of action of pancreatic nesfatin-1/NUCB2
[17].4.3. Antihyperglycemic effects of nesfatin-1
Current observations suggest a potential action of peripheral
nesfatin-1 in controlling of glucose homeostasis [6]. In the study
of Su Y. et al. in 2010, intravenous injection of nesfatin-1 to hyper-
glycemic db/db mice decreased the blood glucose level signifi-
cantly. Anti-hyperglycemic effect of nesfatin-1 is peripheral and
independent of its anorexic effect. This is documented by the fact
that ICV injection of nesfatin-1 did not affect high glucose level
while it lowers food intake.
Nesfatin-1 resulted in elevated glucose-stimulated insulin
release from pancreatic b-cells. Another study has revealed that
nesfatin-1 increases insulin secretion by a direct increase in Ca2+
influx inside pancreatic b-cells through activation of L-type cal-
cium channels [10]. Its effect of increasing intracellular ca2+ level
is glucose dependent. However the relationship between this effect
and ca2+ channel is still unclear.5. Regulation under condition of diabetes mellitus
Type 2 diabetes mellitus (T2DM), the genetically heterogeneous
syndrome, is related to insulin resistance and reduced insulin
secretion. The common form of T2DM is the complex polygenic
diseases [49,50] and is growing at a disturbing level worldwide
even in the developing countries. Raised levels of blood glucose
are reflected to be accountable for additional impediments causing
morbidity and mortality [6].
Latest clinical observations presented a decrease in fasting
plasma nesfatin-1/NUCB2 in type 2 diabetic people compared with
normal controls which has been proposed to play a possible effect
in diabetic hyperphagia [51]. Kuculer et al. in 2016 revealed that
low level of nesfatin 1 in patients with gestational diabetes melli-
tus suggesting that it may have an effect in the pathogenesis of
gestational diabetes mellitus [52]. However, Aydin et.al in 2013,
demonstrated that plasma NUCB2-1 level and its transcription
activity were increased in T2DM patients, which raised the
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or a compensatory mechanism for decreased insulin action [31].
This discrepancy in the level of nesfatin-1/NUCB2 in T2DM may
be due to different study plan, such as case selection and experi-
mental situations [34].
As mentioned above, Nesfatin-1, is a metabolic controller.
Remarkably, injection of nesfatin-1 into the third ventricle may
prevent hepatic glucose creation and stimulate glucose uptake
meaningfully [53]. New studies revealed that the expression of
NUCB2 mRNA in peripheral tissues comprising heart, spinal cord,
pancreas, islets, stomach, and adipose tissue, [33,54] muscle have
crucial physiological roles in body weight and they also contribute
to the pathophysiology of insulin resistance and its associated
metabolic problems in obesity and diabetes [4].
Li et al. established that fasting concentrations of NUCB2 are
significantly lower in T2DM patients. Guo, Y and coworkers [4]
found that NUCB2 mRNA and protein levels of muscle and adipose
tissues were markedly elevated in T2DM patients compared with
controls. The consequence of NUCB2 transcription activity and
insulin resistance rests uncertain now. Additionally these results
recommend that NUCB2 may have a chief role in insulin resistance
or T2DM [4]. The beginning of T2DM classically follows a change in
glucose metabolism symbolized by insulin resistance, atypical fast-
ing glucose levels, and reduced glucose tolerance. Managing of glu-
cose intolerance is often problematic, because of inadequate
findings about the mechanisms by which over-nutrition harms
glucose homeostasis [35].6. Conclusion
In comparison with all other anti-hyperglycemic factors,
nesfatin-1 possibly symbolizes a novel agent of insulin contribu-
tors. Composed, the anorexigenic and anti-hyperglycemic proper-
ties of nesfatin-1 prominently influence both food intake and
glucose metabolism, involving its noteworthy parts in the meta-
bolic regulator of the body. It is necessary that additional works
on nesfatin-1 would be respected to the management of metabolic
diseases particularly for type-2 diabetes and obesity. Nonetheless,
the specific physical and pathophysiological roles of nesfatin-1 on
glucose and energy mechanism now persist unidentified. There-
fore, the physiological effect of elevated plasma NUCB2-1 in
patients with nT2DM and IGT observed in the present study is
uncertain. Different study plan, such as case selection (e.g., obese
vs lean, glycemia level, and diet type) and experimental situations,
may have related to the discrepancy.Conflict of interest
There is no Conflict of Interest to declare in the paper.References
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